Updated Results from the Phase III APL0406 Trial of ATRA/Arsenic Trioxide versus ATRA/Chemotherapy in Nonhigh-Risk APL


Updated Results from the Phase III APL0406 Trial of ATRA/Arsenic Trioxide versus ATRA/Chemotherapy in Nonhigh-Risk APL
Slides from a presentation at ASH 2014 and transcribed comments from a recent interview with Mikkael A Sekeres, MD, MS (1/20/15)
Platzbecker U et al. Improved outcome with ATRA-arsenic trioxide compared to ATRA-chemotherapy in non-high risk acute promyelocytic leukemia — Updated results of the Italian-German APL0406 trial on the extended final series. Proc ASH 2014;Abstract 12.

Dr Sekeres is Professor of Medicine and Director of the Leukemia Program at the Cleveland Clinic Taussig Cancer Institute in Cleveland, Ohio.